Agne Paner, ASH 2019: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Dyscrasias

The ECHELON-1 study compared the experimental brentuximab vedotin plus chemotherapy (A+AVD) to standard ABVD chemotherapy in patients with classical Hodgkin lymphoma. Dr Stephen Ansell (Mayo Clinic, Rochester, MN, USA) discusses the design and findings of the study as well as what was learned and how this will impact the treatment paradigm.  The abstract entitled ‘First-line […]

Hodgkin lymphoma is a challenging disease and a cure, with current therapy, is possible in some but not all patients. Dr Stephen Ansell (Mayo Clinic, Rochester, MN, USA) discusses these challenges and the unmet needs in the treatment of Hodgkin lymphoma.  Dr Stephen Ansell presented an abstract entitled ‘First-line brentuximab vedotin plus chemotherapy to improve […]

Dr Shaji Kumar, one of our Editors-in-Chief for touchREVIEWS in Oncology & Haematology, discusses his presentation at the 63rd ASH Annual Meeting & Exposition on the final overall survival results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Intro: 00:12-00:18 Questions 1. Could […]